Jeanne Lomas, DO
Allergy & Immunology · Amherst, NYNPI 1366684557
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Sanofi at 38.6% of the total. 2025 is the largest year on record at $7,431, more than ten times the $295 reported in 2021.
Across 423 payments — averaging $41.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- ARS Pharmaceuticals Operations, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- Modernatx, Inc.$1K
- GSK$762
- plus $4K from 24 others
Across 41 payments — averaging $7043.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$177K
- Sanofi US Services Inc.$66K
- AstraZeneca$32K
- GSK$13K
What the payments were for
- Consulting fees$1,82510%
- Speaking & faculty fees$5,44831%
- Travel & lodging$8575%
- Food & beverage$9,41053%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 70 | $6,805 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $1,925 |
| Regeneron Healthcare Solutions, Inc. | 74 | $1,850 |
| AstraZeneca | 58 | $1,410 |
| Modernatx, Inc. | 5 | $1,243 |
| GSK | 41 | $762 |
| Novartis | 26 | $568 |
| Pfizer | 12 | $452 |
| CSL Behring | 16 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $357 |
| Amgen(2 entities) | 15 | $292 |
| Genentech USA, Inc. | 15 | $283 |
| Biocryst US Sales Co., LLC | 12 | $255 |
| Galderma Laboratories, L.p. | 8 | $192 |
| Optinose US, Inc. | 7 | $127 |
| Kaleo, Inc. | 6 | $116 |
| Blueprint Medicines Corporation | 5 | $113 |
| Grifols USA, LLC | 3 | $93 |
| Ionis Pharmaceuticals, Inc. | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Pharming Healthcare, Inc. | 2 | $50 |
| Octapharma USA, Inc. | 2 | $42 |
| Organon | 1 | $31 |
| Lilly USA, LLC | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Merck | 1 | $17 |
| AbbVie | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,639 in reported general payments places this provider in the 85th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $40,844 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,586 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,161 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,820 |
| Azelastine Hcl | 30 | $1,000 |
| Ipratropium Bromide | 36 | $834 |
| Montelukast Sodium | 33 | $638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $619 |
| Famotidine | 31 | $437 |
| Fluticasone Propionate | 40 | $430 |
| Hydroxyzine Hcl | 12 | $163 |
| Prednisone | 18 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $762 | $5,58612 claims |
| AstraZenecaSymbicort | $1,410 | $3,82015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Amherst
- Ujwala KazaNew York$1.1M
- Syed MustafaRochester$948K
- Robert SporterNew York$946K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$643K
- Robert TamayevRego Park$321K
- Richard InselNew York$269K
- Payel GuptaBrooklyn$256K
- Luz FonacierMineola$237K
- Mark Davis-LortonTarrytown$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.